Heffeter, P., Atil, B., Kryeziu, K., Groza, D., Koellensperger, G., Körner, W., . . . Berger, W. (2013). The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo(). Elsevier Science Ltd.
استشهاد بنمط شيكاغوHeffeter, Petra, et al. The Ruthenium Compound KP1339 Potentiates the Anticancer Activity of Sorafenib in Vitro and in Vivo(). Elsevier Science Ltd, 2013.
MLA استشهادHeffeter, Petra, et al. The Ruthenium Compound KP1339 Potentiates the Anticancer Activity of Sorafenib in Vitro and in Vivo(). Elsevier Science Ltd, 2013.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.